Samuel Isaly Holdings 13F: Latest OrbiMed Advisors Portfolio Changes
OrbiMed Advisors. Healthcare-focused investment firm (~$4.9B AUM). Global healthcare leader.
As of the latest Q2 2026 13F filing, Samuel Isaly (managing OrbiMed Advisors) reported a public portfolio value of $5.4B with 129 positions. This page tracks latest holdings, latest 13F changes, top buys, top sells, and top holdings from the public filing. The top recent buy was LLY. The top recent sell was ELVN.
Open interactive portfolioLatest 13F portfolio changes
Samuel Isaly holdings 13F summary: the latest OrbiMed Advisors portfolio changes show top holdings including EDGEWISE THERAPEUTICS, ENLIVEN THERAPEUTICS, ELI LILLY &, MBX BIOSCIENCES, and SINOVAC BIOTECH, reported top buys such as ELI LILLY &, ASTRAZENECA, STRUCTURE THERAPEUTICS, and GUARDANT HEALTH, and top sells or reductions such as ENLIVEN THERAPEUTICS, MBX BIOSCIENCES, MYRIAD GENETICS, and SIONNA THERAPEUTICS.
Latest filing metadata: quarter Q2 2026; report date 2026-06-30; filing date 2026-08-14; disclosure source SEC 13F.
Samuel Isaly 13F portfolio and latest holdings overview
Samuel Isaly's Q2 2026 13F holdings show OrbiMed Advisors reporting 129 positions with a disclosed portfolio value of $5.4B. For readers searching Samuel Isaly 13F holdings, Samuel Isaly portfolio, OrbiMed Advisors holdings, or latest 13F changes, the latest top holdings include EDGEWISE THERAPEUTICS, ENLIVEN THERAPEUTICS, ELI LILLY &, MBX BIOSCIENCES, and SINOVAC BIOTECH.
The three largest reported positions add up to roughly 24.3%, which helps readers judge portfolio concentration rather than just headline AUM. The largest reported sector exposure is Health Care at 79.7% of the disclosed portfolio. This makes the page useful for comparing the manager's actual disclosed exposure with market narratives around the same names.
The latest change data highlights reported buys such as ELI LILLY &, ASTRAZENECA, STRUCTURE THERAPEUTICS, GUARDANT HEALTH, and PRAXIS PRECISION MEDICINES I and reported reductions or exits such as ENLIVEN THERAPEUTICS, MBX BIOSCIENCES, MYRIAD GENETICS, SIONNA THERAPEUTICS, and ARGENX SE. Those changes should be read as historical disclosure signals, not as real-time trade alerts.
The filing metadata lists report date 2026-06-30, filing date 2026-08-14, SEC accession 0001172661-26-003740. SEC 13F reports are normally published up to 45 days after quarter end, so the data is best used to understand institutional positioning after the fact rather than to infer today's exact portfolio.
Samuel Isaly portfolio analytics
the top five positions account for 31.7% of disclosed value; the largest sector exposure is Health Care at 79.7%; reported buy and sell activity implies roughly 71.0% turnover this period; cost-basis P&L across 116 tracked positions averages 224.5% (54/74 currently in profit).
Top reported holdings
| Holding | Reported value | Weight | Quarter change |
|---|---|---|---|
| EWTX whale holders EDGEWISE THERAPEUTICS INC | $630.5M | 11.9% | Held |
| ELVN whale holders ENLIVEN THERAPEUTICS INC | $343.9M | 6.5% | Reduced |
| LLY whale holders ELI LILLY & CO | $309.3M | 5.9% | Increased |
| MBX whale holders MBX BIOSCIENCES INC | $189.3M | 3.6% | Reduced |
| SVA whale holders SINOVAC BIOTECH LTD | $184.5M | 3.5% | Held |
| AZN whale holders ASTRAZENECA PLC | $171.1M | 3.2% | Increased |
| GPCR whale holders STRUCTURE THERAPEUTICS INC | $118.6M | 2.2% | Increased |
| SION whale holders SIONNA THERAPEUTICS INC | $112.4M | 2.1% | Reduced |
| CRVS whale holders CORVUS PHARMACEUTICALS INC | $107.0M | 2.0% | Held |
| AVBP whale holders ARRIVENT BIOPHARMA INC | $105.2M | 2.0% | Held |
Top buys
- LLY whale holders — ELI LILLY & CO ($309.3M)
- AZN whale holders — ASTRAZENECA PLC ($171.1M)
- GPCR whale holders — STRUCTURE THERAPEUTICS INC ($118.6M)
- GH whale holders — GUARDANT HEALTH INC ($87.6M)
- PRAX whale holders — PRAXIS PRECISION MEDICINES I ($77.0M)
- PRLD whale holders — PRELUDE THERAPEUTICS INC ($73.2M)
Top sells
- ELVN whale holders — ENLIVEN THERAPEUTICS INC ($343.9M)
- MBX whale holders — MBX BIOSCIENCES INC ($189.3M)
- N/A whale holders — MYRIAD GENETICS INC ($122.9M)
- SION whale holders — SIONNA THERAPEUTICS INC ($112.4M)
- ARGX whale holders — ARGENX SE ($86.2M)
- QURE whale holders — UNIQURE NV ($83.3M)
Allocation
- Health Care: 79.7%
- Other: 19.3%
Data notes
Report date: 2026-06-30
Disclosure source: SEC 13F
SEC 13F filings are delayed public disclosures and do not include every asset class, short positions, or real-time trades.
Related investor portfolios
- Ray Dalio 13F holdings and Bridgewater Associates portfolio changes — Bridgewater Associates
- Ruane, Cunniff & Goldfarb 13F holdings and portfolio changes — Ruane, Cunniff & Goldfarb
- Lee Ainslie 13F holdings and Maverick Capital portfolio changes — Maverick Capital
- Polen Capital 13F holdings and Polen Capital Management portfolio changes — Polen Capital Management
- Baker Bros. Advisors 13F holdings and portfolio changes — Baker Bros. Advisors
- Dev Kantesaria 13F holdings and Valley Forge Capital Management portfolio changes — Valley Forge Capital Management
- Chase Coleman 13F holdings and Tiger Global Management portfolio changes — Tiger Global Management
- Stanley Druckenmiller 13F holdings and Duquesne Family Office portfolio changes — Duquesne Family Office
Learn more in Whale Analyzer Academy
Learn more in Whale Analyzer Academy:
Frequently asked questions
Samuel Isaly 13F Holdings
The Q2 2026 13F profile for Samuel Isaly and OrbiMed Advisors shows 129 reported positions, $5.4B in disclosed portfolio value, and top holdings including EDGEWISE THERAPEUTICS, ENLIVEN THERAPEUTICS, ELI LILLY &, MBX BIOSCIENCES, and SINOVAC BIOTECH.
What is Samuel Isaly buying? Latest 13F changes
The latest tracked change data for Samuel Isaly highlights reported buys such as ELI LILLY &, ASTRAZENECA, STRUCTURE THERAPEUTICS, and GUARDANT HEALTH and reported sells or reductions such as ENLIVEN THERAPEUTICS, MBX BIOSCIENCES, MYRIAD GENETICS, and SIONNA THERAPEUTICS.
OrbiMed Advisors top holdings
OrbiMed Advisors top holdings are summarized from public disclosures with reported values, weights, portfolio concentration, top buys, top sells, and filing metadata where available.
Samuel Isaly buys and sells
Use the top buys and top sells sections above to compare Samuel Isaly's reported additions, reductions, exits, and latest portfolio activity against other tracked investors.
How delayed is Samuel Isaly's 13F data?
SEC Form 13F requires institutional investment managers with $100M+ in US equities to disclose their holdings quarterly. Read our comprehensive 13F guide for timing, coverage, and limitations. Read the Whale Analyzer 13F guide.